Search results for "Breakthrough Pain"

showing 10 items of 40 documents

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct

Breakthrough pain in patients with abdominal cancer pain.

2014

Abstract OBJECTIVE: Characterization of breakthrough cancer pain (BTcP) in patients with abdominal cancer is lacking. The aim of this study was to assess the characteristics of BTcP in patients with abdominal cancer pain. PATIENTS AND METHODS: In an observational cohort study, from a consecutive sample of patients admitted to a pain relief and supportive care unit for a period of 13 months, patients with abdominal disease due to cancer, including primary cancer or metastases, were assessed for the presence of chronic abdominal pain; its mechanism, intensity of background pain, and pain flares, which were distinguishable from the baseline pain, were recorded. Patients presenting with pain fl…

Malecancer painmedicine.medical_specialtyPalliative careAnalgesicSettore MED/41 - AnestesiologiaDiseaseSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsInternal medicinemedicineHumansPain ManagementIn patientcancer pain; breakthrough pain; abdominal pain; epidemiology; opioidsNeoplasm MetastasisAgedPain MeasurementAnalgesicsbusiness.industryPalliative Careabdominal painopioidsCancerbreakthrough painmedicine.diseaseAnesthesiology and Pain MedicineFemaleepidemiologyObservational studyNeurology (clinical)Chronic PainCancer painbusinessCohort study
researchProduct

Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomiz…

2015

Fentanyl products have shown superiority to oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use appropriate patient selection, and drugs have been compared by using different rationales.The aim of this randomized, crossover, controlled study was to compare efficacy and safety of fentanyl buccal tablets (FBTs) and oral morphine (OM), given in doses proportional to opioid daily doses.Cancer patients with pain receiving ≥60 mg or more of oral morphine equivalents per day and presenting with ≤3 episodes of BTcP per day were included. In a randomized, crossover manner, patients received FBT or OM at doses proportional to the daily opioid regimen…

Malefentanyl buccal tabletContext (language use)FentanylNeoplasmsmedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain MeasurementCross-Over StudiesMorphinebusiness.industrybreakthrough pain; Cancer pain; fentanyl buccal tablet; oral morphine; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Administration BuccalPatient PreferenceBuccal administrationMiddle Agedbreakthrough painCrossover studyAnalgesics OpioidFentanylRegimenTreatment OutcomeAnesthesiology and Pain MedicineOpioidoral morphineAnesthesiaMorphineFemaleNeurology (clinical)Cancer painbusinessmedicine.drug
researchProduct

Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A …

2016

Context Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use an appropriate patient selection, and drugs have been compared using a different rationale. Objectives The aim of this randomized, crossover, controlled study was to compare the efficacy and safety of fentanyl pectin nasal spray (FPNS) and oral morphine (OM), given in doses proportional to opioid daily doses. Methods Cancer patients with pain receiving ≥60 mg of OM equivalents/day and presenting with ≤3 episodes of BTcP/day were included. Patients received, in a randomized, crossover manner, FPNS or OM at doses proportional to the d…

Malefentanyl pectin nasal spraymedicine.medical_treatmentAdministration OralContext (language use)Fentanyl03 medical and health sciences0302 clinical medicinemedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain MeasurementAnalgesicsCross-Over StudiesMorphinebusiness.industryNasal SpraysMiddle Agedbreakthrough painCrossover studyFentanylRegimenTreatment OutcomeAnesthesiology and Pain MedicineOpioidNasal sprayoral morphine030220 oncology & carcinogenesisAnesthesiaMorphinePectinsFemaleNeurology (clinical)businessCancer painbreakthrough pain; Cancer pain; fentanyl pectin nasal spray; oral morphine; Nursing (all)2901 Nursing (miscellaneous); Neurology (clinical); Anesthesiology and Pain Medicine030217 neurology & neurosurgerymedicine.drug
researchProduct

Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients

2013

Abstract OBJECTIVES: To assess the level of pain intensity at which patients feel the impetus to ask for a breakthrough cancer pain (BTcP) medication, and level of pain intensity at which patients consider they have achieved acceptable pain control after receiving a BTcP medication. METHODS: A consecutive sample of patients who were receiving oral morphine equivalents equal to or more than 60 mg daily, and were prescribed rapid onset opioids for the management of episodes of BTcP, were included in the study. Focused educational activities regarding BTcP and numerical scales were established during hospital admission. At discharge patients were interviewed to find out what was the pain inten…

Malemedicine.medical_specialtyCoping (psychology)Palliative careBreakthrough PainPainSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLEadvanced cancer patientNeoplasmsHumansPain ManagementMedicineOral morphineAgedPain MeasurementMorphinebusiness.industrybreakthrough pain; advanced cancer patients; epidemiologic studyGeneral MedicineMiddle Agedbreakthrough painAdvanced cancerAnalgesics OpioidClinical trialepidemiologic studyPhysical therapyFemalebusinessCancer pain
researchProduct

Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiol…

2020

Abstract Abstract Background: The different operational definitions of breakthrough cancer pain (BTcP) has generated unclear epidemiological data. Methods: A consecutive sample of patients was categorized on the basis of their background pain intensity, background analgesic treatment, and the presence of BTcP. Results: A total of 265 patients were surveyed; 117 patients had background pain and 91 patients presented peaks of pain intensity distinguishable from background pain. Of 117 patients with background pain, 49 patients were re-assessed after optimization of background analgesia (T1) within a mean of 8.2 days. Pain intensity significantly decreased in comparison with values recorded at…

Malemedicine.medical_specialtyEpidemiologyBreakthrough PainAnalgesicOpioidSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLENeoplasmsSurveys and QuestionnairesEpidemiologyMedicineHumansPain ManagementCancer painPain MeasurementAnalgesicsbackground cancer painbusiness.industryMedicine (all)General MedicineBreakthrough pain; Cancer pain; Epidemiology; Opioids; Analgesics Opioid; Breakthrough Pain; Female; Humans; Male; Neoplasms; Pain Management; Pain Measurement; Surveys and Questionnaires; Medicine (all)breakthrough painIntensity (physics)OpioidsAnalgesics OpioidAnesthesiaepidemiologic studyFemaleCancer painbusinessbackground cancer pain; breakthrough pain; epidemiologic study
researchProduct

Breakthrough Pain in Advanced Cancer Patients Followed at Home: A Longitudinal Study

2009

The aim of this study was to longitudinally assess breakthrough pain (BP) in advanced cancer patients who were admitted to home palliative care. One hundred and one consecutive patients who were admitted to one of the two home care programs and were representative of the cancer population followed at home in Italy were included. Patients were excluded only if at admission they were cognitively impaired or too unwell to provide reliable answers to questions regarding data collection. At admission (T(0)), and one month later (T(1)), data were recorded about the pharmacological treatment of background pain and its effectiveness; the presence of BP and its intensity, duration, and number of epi…

Malemedicine.medical_specialtyPalliative careAnalgesicPopulationPainComorbidityRisk AssessmentMedication prescriptionadvanced cancer patientRisk FactorsNeoplasmsInternal medicineBreakthrough painmedicineHumansLongitudinal StudieseducationSurvival rateGeneral NursingAgededucation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)longitudinal studymedicine.diseaseHome Care ServicesSurvival AnalysisComorbiditySurvival RateAnesthesiology and Pain MedicineItalyPhysical therapyFemaleNeurology (clinical)businessCancer painJournal of Pain and Symptom Management
researchProduct

Nurse-based monitoring and management of breakthrough pain in an acute pain relief and palliative care unit

2016

To assess the nurses' performance in assessing, treating, and documenting breakthrough pain (BTP) in a palliative care unit where traditionally there is continuous training.The study was performed in an acute palliative care unit. Once a week, a research nurse examined the documentation regarding all the episodes of BTP registered in a specific pain chart, designed by the institutional nurse board, as part of the routine nurse activity.The charts of 50 consecutive eligible patients (32 M/18 F), were analysed. The mean number of episodes/patient was 3.3 (SD 1.61; range 1-7). 166 episodes occurred. The main BTP pain intensity was 7.06 (SD 0.82). In 7 episodes, pain intensity was not evaluated…

Not evaluatedPalliative carebusiness.industryassessmentBreakthrough PainopioidsGeneral Medicinebreakthrough pain03 medical and health sciences0302 clinical medicinenursingNursing030220 oncology & carcinogenesisMedicine030212 general & internal medicineCancer painbusinessCancer painAcute painHospital Practice
researchProduct

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct

Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.

2012

Abstract OBJECTIVES: The aim of this study was to compare the efficacy and safety of doses of fentanyl buccal tablet (FBT) proportional to doses of opioids used for background analgesia versus dose titration starting with the minimal dose for the management of breakthrough cancer pain (BTcP). METHODS: A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60 mg of oral morphine equivalents and having acceptable background analgesia, were selected for a multicenter unblinded study. Forty-one patients were randomized to receive FBT in doses proportional to the daily opioid doses for four consecutive episodes of BTcP (group P). Forty-one patients underwe…

OralMaleDose titrationfentanyl buccal tabletAdministration OralOpioidDosing fentanylSettore MED/42 - Igiene Generale E ApplicataDose titrationlaw.inventionDose-Response RelationshipRandomized controlled triallawNeoplasmsFentanyl Buccal TabletMedicineHumansRapid onset opioidsDrug Dosage CalculationsCancer painAgedPain MeasurementAnalgesicsDose-Response Relationship DrugBreakthrough pain; Cancer pain; Dose titration; Fentanyl buccal tablet; Rapid onset opioids; Administration Oral; Aged; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Titrimetry; Drug Dosage Calculations; Medicine (all)business.industryMedicine (all)Breakthrough PainTitrimetryCancerGeneral MedicineBuccal administrationfentanyl buccal tablet; breakthrough cancer pain; randomized clinical trialMiddle Agedmedicine.diseaserandomized clinical trialAnalgesics OpioidFentanylbreakthrough cancer painOpioidAnesthesiaAdministrationFemaleDrugbusinessCancer painmedicine.drugTabletsCurrent medical research and opinion
researchProduct